Five Under 5: Top Oncology Videos for the Week of 6/8
The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.
Related Articles
Hematologists Highlight Notable Insights From the 2025 EHA Congress
Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.
Intentional Treatment Sequencing Strategies Optimize SCLC and NSCLC Management
Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.
Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resectable Esophageal/GEJ Cancer
Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.
Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC
TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.
Adjuvant Atezolizumab Plus mFOLFOX6 Improves DFS in dMMR Colon Cancer
Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.
Early Switch With Camizestrant Plus Continued CDK4/6 Inhibition Nearly Doubles PFS in ESR1-Mutant, ER+/HER2– Advanced Breast Cancer
Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.
Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma
Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.
Perioperative Durvalumab Plus FLOT Represents New SOC in Resectable Gastric/GEJ Adenocarcinoma
The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.
NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH
Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.